Assembly Biosciences Inc
ASMB
查看详细走势图
32.730USD
-3.450-9.54%
收盘 12/23, 16:00（美东）报价延迟15分钟
517.69M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-9.54%
5天
-2.30%
1月
-14.99%
6月
+88.21%
今年开始到现在
+107.41%
1年
+119.37%
查看详细走势图
TradingKey Assembly Biosciences Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Assembly Biosciences Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名69/404位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价41.00。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Assembly Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
强力买入
评级
41.000
目标均价
+15.88%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Assembly Biosciences Inc亮点
亮点风险
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Assembly Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Assembly Biosciences Inc简介
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
公司代码ASMB
公司Assembly Biosciences Inc
CEO
网址https://www.assemblybio.com/
常见问题
Assembly Biosciences Inc(ASMB)的当前股价是多少？
Assembly Biosciences Inc(ASMB)的当前股价是 32.730。
Assembly Biosciences Inc的股票代码是什么？
Assembly Biosciences Inc的股票代码是ASMB。
Assembly Biosciences Inc股票的52周最高点是多少？
Assembly Biosciences Inc股票的52周最高点是39.705。
Assembly Biosciences Inc股票的52周最低点是多少？
Assembly Biosciences Inc股票的52周最低点是7.750。
Assembly Biosciences Inc的市值是多少？
Assembly Biosciences Inc的市值是517.69M。
Assembly Biosciences Inc的净利润是多少？
Assembly Biosciences Inc的净利润为-40.18M。
现在Assembly Biosciences Inc(ASMB)的股票是买入、持有还是卖出？
根据分析师评级，Assembly Biosciences Inc(ASMB)的总体评级为--，目标价格为41.000。
Assembly Biosciences Inc(ASMB)股票的每股收益（EPS TTM）是多少
Assembly Biosciences Inc(ASMB)股票的每股收益（EPS TTM）是-4.603。
相关品种
